Silk Road Medical, Inc (NASDAQ:SILK) Given Average Recommendation of “Hold” by Analysts

Silk Road Medical, Inc (NASDAQ:SILK) has received a consensus rating of “Hold” from the eleven brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $22.55.

SILK has been the subject of several recent research reports. Argus raised Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Thursday, March 7th. Piper Sandler upped their target price on Silk Road Medical from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. upped their target price on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Finally, Stifel Nicolaus upped their target price on Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, February 29th.

Insider Buying and Selling

In other Silk Road Medical news, CAO Marie L. Jones sold 2,602 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total value of $44,676.34. Following the sale, the chief accounting officer now owns 76,894 shares of the company’s stock, valued at approximately $1,320,269.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Silk Road Medical news, CAO Marie L. Jones sold 2,602 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total value of $44,676.34. Following the sale, the chief accounting officer now owns 76,894 shares of the company’s stock, valued at approximately $1,320,269.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin M. Klemz sold 2,497 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total value of $42,873.49. Following the completion of the sale, the executive vice president now directly owns 165,194 shares in the company, valued at approximately $2,836,380.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,457 shares of company stock valued at $351,247. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. CWM LLC grew its stake in shares of Silk Road Medical by 151.5% in the 4th quarter. CWM LLC now owns 2,563 shares of the company’s stock valued at $31,000 after purchasing an additional 1,544 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Silk Road Medical by 1,293.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock valued at $31,000 after purchasing an additional 2,342 shares during the last quarter. RiverPark Advisors LLC purchased a new position in shares of Silk Road Medical in the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC grew its stake in shares of Silk Road Medical by 879.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,210 shares of the company’s stock valued at $52,000 after purchasing an additional 3,780 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Silk Road Medical in the 4th quarter valued at approximately $62,000.

Silk Road Medical Trading Up 3.1 %

Shares of SILK stock opened at $20.90 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 7.95 and a quick ratio of 6.97. The company has a market cap of $824.30 million, a price-to-earnings ratio of -15.26 and a beta of 1.43. The stock has a 50 day simple moving average of $17.80 and a 200-day simple moving average of $13.80. Silk Road Medical has a 1-year low of $6.08 and a 1-year high of $43.51.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.04. Silk Road Medical had a negative return on equity of 35.12% and a negative net margin of 29.02%. The firm had revenue of $48.50 million during the quarter, compared to the consensus estimate of $44.67 million. During the same period in the prior year, the company earned ($0.43) EPS. The firm’s revenue was up 20.9% compared to the same quarter last year. On average, equities research analysts expect that Silk Road Medical will post -1.43 EPS for the current fiscal year.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.